Kura Oncology forms Caspian unit, which raised $50.0 million in preferred stock financing
Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for diabetes and other cardiometabolic diseases. On September 8, 2026, Caspian completed a $50.0 million Series A preferred stock financing, in which Kura invested $4.3 million and which left Kura holding about 49.2% of Caspian's outstanding capital stock.
Key points
- Caspian completed a $50.0 million private Series A preferred stock financing on September 8, 2026.
- Kura invested $4.3 million and held about 49.2% of Caspian's outstanding capital stock after the financing.
- Kura contributed rights to menin inhibitors, including KO-7246, to Caspian for Caspian common stock and reimbursement of up to $1.5 million in maintenance costs.
- Kura will provide research, development and administrative services to Caspian under a services agreement with a one-year initial term.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.